ABSTRACT-A newly discovered antifungal agent, pramanicin, within the therapeutically effective concentration range (4 -100 mM), inhibits the tone of phenylephrine (PE)-precontracted dog carotid arterial rings in a concentration-dependent manner and leads to gradual development of relaxation. However, pramanicin had no effect on rings precontracted with 100 mM KCl or on endothelium-denuded rings. Thus, inhibition by pramanicin of PE-induced contraction was endothelium-dependent. Preincubation of 100 mM pramanicin with carotid arterial rings for 30 min did not significantly affect the concentration-contraction response to PE, but almost completely inhibited the endothelium-dependent relaxation response to subsequent addition of 3 m M carbachol or 100 m M pramanicin. This irreversible inhibition of endotheliumdependent relaxation, which is independent of extracellular Ca
Antifungal agents are widely used not only in human and veterinary medicine, but are also applied as disinfectants or preservatives in industrial environments where control of fungal growth is desirable. One class of antifungal compounds, having the general structure of a polar, highly functionalized head group and a simple fatty acid side chain (1 -5) , act through a variety of mechanisms including the inhibition of sterol biosynthesis, sphingofungin formation and cell wall generation. However, the actions and toxicities of such agents in mammals have not been systematically studied. Indeed, some potent antimicrobial agents exhibit high levels of toxicity and have limited therapeutic value when used systemically, such as cyclopiazonic acid and thapsigargin. Since they have specific and potent inhibitory actions on sarcoplasmic recticulum Ca 2+ -ATPase, they are now widely used as pharmacological tools for studying the regulation of cell Ca 2+ (6 -9) Recently, a potent antifungal agent, pramanicin (see Fig. 1 for chemical structure), with a highly functionalized polar head group and a simple, long aliphatic side chain was isolated from a fungal fermentation (10) and biosynthesized (11) . Pramanicin exerts a potent anti-growth effect on a wide range of fungal organisms with minimal inhibitory concentrations (MIC) of 20 -100 mM (10) . Despite the suggestion of various clinical applications (10) , its pharmacological effects on mammalian cells and tissues are not clear. The purpose of this work, therefore, is to communicate our novel findings on the in vitro functional vascular effects of pramanicin using dog carotid artery (for contractility study). Our results suggest that pramanicin elicited disturbances on vasorelaxation via its selective action on the endothelial cells. 
MATERIALS AND METHODS

Animals and vascular preparations
Mongrel dogs weighing 15 -40 kg, either male or female, were killed with an intravenous overdose of pentobarbital (100 mg/ kg). This procedure is in accordance with the guidelines of our University Ethics Committee. The carotid artery segments were removed and placed in Kreb's physiological saline solution containing: 115.5 mM NaCl, 4.6 mM KCl, 1.2 mM MgSO4, 1.1 mM NaH2PO4, 2.5 mM CaCl2, 21.9 mM NaHCO 3 and 11.1 mM D-glucose, prepared in double-distilled water. The solution was continually aerated with a 95% O2 / 5% CO2 gas mixture to maintain a pH near 7.4 at room temperature. After surrounding fatty and connective tissues were removed, the carotid arteries were cut into ring segments 3 -5 mm in width and carefully suspended in a bath chamber containing 10 ml aerated Kreb's solution at 37°C between two stainless steel hooks with a fixed bottom hook and an upper hook connected to a force transducer, which was connected to a Beckman R-611 recording dynograph (Beckman, San Ramon, CA, USA). The optimal active tension development in response to hyperosmotically added 100 mM KCl was observed at a resting tension of 10 g. Freshly dissected vascular tissues and tissues allowed to recover after storage in the cold (4°C) overnight developed the same maximal contractile responses to hypertonically added 100 mM KCl in the presence of 10 mM phentolamine (to inhibit the action of any norepinephrine released from the nerve endings) and to 100 mM phenylephrine. Thus, both freshly dissected and overnight-stored tissues were used for the contractility studies.
Measurement of isometric contraction
Following equilibration for 90 -120 min under a resting tension of 10 g, recording of isometric tension development was made after 3 -4 consecutive and consistent contractions occurred in response to 100 mM KCl. To obtain endothelium-denuded preparations, the endothelial cell lining of the vascular ring segments was removed by gently rubbing the inner surfaces against the teeth of the forceps. This protocol did not affect the contraction induced by KCl or phenylephrine (PE), but completely prevented the relaxation induced by 3 mM carbachol of the rings precontracted with 100 mM PE. Those endothelium-denuded rings, which responded poorly or not at all to carbachol, were completely relaxed by 1 mM sodium nitroprusside (SNP). A 30-min period between two consecutive stimulations was allowed for thorough washout of the drugs. A contraction to 100 mM KCl was always obtained at the end of the experiment (usually 4 -5 h after the initial control KCl-contraction). The magnitude of this KCl-contraction was usually better than 90% of the initial KCl-contraction.
Chemicals
Pramanicin (>98% pure, chemical structure shown in Fig. 1.) was prepared from cultures of Stagonospora Sp. ATCC 74253 (American Type Culture Collection, Rockville, MD, USA) according to the method described recently (11) . Material from the reverse-phase chromatography step was recrystallized from methanol : water (approx. 1:1). Pramanicin crystals were dissolved in dimethyl sulfoxide (DMSO) to give a stock solution of 40 mM (stored at -20°C and used within one week), and this stock solution was diluted in water to 10 mM as the working solution on the day of the experiment. All inorganic and organic chemicals used for contractility studies were purchased as the reagent grade from commercial sources including Sigma (St. Louis, MO, USA) and Aldrich (Mississauga, ON, Canada). Culture media and reagents used for cell culture were purchased from Gibco (Grand Island, NY, USA). Distilled and de-ionized water was used for the preparation of solutions. Figure 2 shows a set of representative tracings of contractions of canine carotid arterial rings with functionally intact endothelium. Tracings in Fig. 2A indicate that the preparation gives stable contractile responses to 100 mM KCl and 100 m M PE, with reproducible relaxation responses to 1 mM carbachol. Typically, as shown in Table 1 , carbachol caused vascular relaxation by 65 -96% of the responses to PE (>95% were sensitive to 10 mM sodium nitroprusside). DMSO (0.25%), which is the final concentration of DMSO present in pramanicin-treated preparations, affected neither the PE contraction nor the relaxation induced by carbachol. The residual contraction to PE in the presence of carbachol or pramanicin was abolished by 10 m M SNP. The magnitude of the contractile response to 100 mM KCl at the end of each experiment remained 98.5 ± 3.5% (n = 31) of that of the KCl-response obtained in the beginning of the experiment. In all experiments, addition of pramanicin £100 m M had little or no effect on the resting tension. At 100 mM, in 25 -30% of the rings, pramanicin reversibly caused a small increase in tone amounting to 5 -10% of the maximal contraction to KCl. However, when incubated with 300 m M pramanicin for 30 min, all rings elicited an irreversible contraction of about 10 -15% of the maximal KCl-contraction. Therefore, for most of our studies, we used 100 mM pramanicin.
RESULTS
Effect of pramanicin on the resting tension
Pramanicin pretreatment irreversibly inhibited carbacholinduced relaxation
Tracings in Fig. 2B demonstrate that preincubation of the vascular rings with 100 m M pramanicin for 30 min resulted in the loss of relaxation induced by 1 mM carbachol at the plateau phase of a second contractile response to 100 mM PE (16.5 ± 11.5% inhibition of the contraction to PE, n = 8).
However, subsequent addition of 1 m M SNP totally relaxed the vascular ring, indicating that the loss of relaxation is not due to non-selective loss of the ability of the vascular smooth muscle to relax. Pretreatment with 100 mM pramanicin had no effect on the maximal contraction and the concentration-response profile of PE-contraction (EC50: 13.1 ± 4.5 mM vs 15.5 ± 6.3 mM for the control value, n = 4). Subsequent addition of 100 m M pramanicin at the peak of PE-contraction had no further effect (98 ± 3% of PE con- Fig. 2 . The effects of 100 mM pramanicin (PMC) on the contractile response of dog carotid artery to 100 m M phenylephrine (PE). A: Control responses to hypertonically added 100 mM KCl, 100 mM PE and 3 m M carbachol (Carb), which caused greater than 70% relaxation. Addition of 0.25% dimethyl sulfoxide (DMSO) at the plateau phase of the PE-contraction did not affect the magnitude of the PE-contraction or the subsequent relaxation induced by Carb. After thorough wash-out, greater than 80% of the PE response was obtained and Carb-relaxation was also reproducible. The Carb-resistant component was further relaxed by 1 mM sodium nitroprusside (SNP), and the KCl response at the end of the experiment was within 90% of the initial KCl response. B: When 100 m M PMC was preincubated with the preparation for 30 min following the control responses to KCl, PE and Carb, the subsequent relaxation of the PE contraction to Carb was completely blocked, but the vascular preparation elicited complete relaxation to SNP. In a subsequent PE contraction, addition of 100 m M PMC at the plateau phase failed to induce relaxation, which on the contrary remained effective with 1 m M SNP. C: If the preparation was exposed to 100 mM PMC at the plateau phase of the PE-contraction for the first time, a relaxation response was immediately, but slowly developed. However, this slow relaxation was not observed upon the second application of PMC (not shown) or addition of 3 m M Carb at the plateau phase of the subsequent PE-contraction. % Relaxation is normalized by the total relaxation of the PE-contraction in response to 10 m M sodium nitroprusside (SNP), which usually inhibited >95% of the PE-contraction. N = number of vascular rings from at least 3 dogs. Dimethyl sulfoxide (DMSO) is used as solvent for PMC. Endothelium-denuded rings were prepared by incubating the rings in the bath chamber with 300 mg /ml saponin for 5 min followed by repeated washing with the standard bath medium. The effective removal of endothelium is indicated by the lack of relaxation to the addition of 3 m M carbachol (Carb).
traction after pramanicin treatment, n = 4). We have also observed that the optimal preincubation time required to maximally (>90%) inhibit the carbachol-induced relaxation was 30 min. Addition of 100 m M pramanicin 15, 30 and 45 min prior to the addition of carbachol to PE-precontracted rings to induce relaxation resulted in decreasing magnitude of relaxation with the preincubation time ( Table 2 ). In endothelium-denuded preparations, addition of 1 mM carbachol caused little or no relaxation of PE-precontracted tissues (tracings not shown, but see Table 1 ). Furthermore, preincubation with 0.25% DMSO vehicle or 100 mM pramanicin, did not significantly modify the subsequent carbachol-induced relaxation in endothelium-intact vascular rings.
Pramanicin induced relaxation to phenylephrine-induced contraction Although Fig. 2B shows that pramanicin pretreatment had little effect on the magnitude of the PE-contraction, when 100 m M pramanicin was applied for the first time at the plateau phase of the PE-contraction in endotheliumintact vascular rings, relaxation developed slowly, reaching a maximum (62.0 ± 20.0% of the maximal relaxation induced by 10 mM SNP, n = 8) at 16 ± 2.5 min (n = 8) following the addition of pramanicin as shown in Fig. 2C and Table 1 . The magnitude of the slow relaxation induced by pramanicin represented 75.3 ± 25.3% (n = 8) of the control fast relaxation response to 3 mM carbachol. Following pretreatment with 100 mM pramanicin for 30 min, repeated wash over one hour failed to restore carbachol-induced relaxation in endothelium-intact preparations; (15.1 ± 10.3% inhibition of PE-contraction, compared to the relaxation of a time control studied in parallel, which was 79.5 ± 8.2%; n = 4). Figure 3 shows that pramanicin induced vascular relaxation of endothelium-intact dog carotid rings precontracted with 100 mM PE in a concentration-dependent manner and inhibited the subsequent relaxation induced by 3 m M carbachol (following exposure of the vascular preparation to pramanicin for 45 min). The IC50 values for pramanicin on these two events were quite similar, around 15 mM. We 
Rings were first pre-incubated with PMC for 15 -20 min in bath medium containing 2.5 mM Ca 2+ or Ca 2+ -free plus 1 mM EGTA and then returned to physiological medium containing 2.5 mM Ca 2+ before stimulation with 100 m M PE and subsequent relaxation with 3 m M Carb. Sodium nitroprusside (SNP, 10 m M) was added at the end to determine the maximal relaxation, which was used as 100% for data normalization. also investigated whether extracellular Ca 2+ was required for the action of pramanicin. This was tested by preincubation of 100 mM pramanicin with the endothelium-intact rings in Ca
2+
-free medium (containing 1 mM EGTA) for 30 -45 min after control PE (100 m M)-responses in the presence and absence of 3 mM carbachol in Ca
-containing medium (before-drug control). Then the preparations were returned to Ca 2+ -containing medium for 30 min and subsequently stimulated with 100 mM PE. The subsequent relaxation by 3 mM carbachol was again tested. These experiments showed that the inhibitory effect of pramanicin on the endothelial function retained in Ca 2+ -free medium as well. Pramanicin (100 m M) under these experimental conditions significantly inhibited carbachol-induced relaxation compared to the non-significant inhibition by DMSO in the time-control. These findings, as summarized in Table 2 , suggest that pramanicin-induced endothelial dysfunction and ultimate cell damage does not require extracellular Ca
. To test whether pramanicin acts directly at the endothelial muscarinic receptor site, the loss of endothelium-dependent relaxation by pretreatment with 100 m M pramanicin was tested with 100 mM ATP and 3 m M cyclopiazonic acid, in addition to 3 mM carbachol. Similarly defective relaxation was found in all cases (Table 3) .
Effect of L-N
G -monomethyl-arginine pretreatment on endothelium-dependent vascular relaxation induced by pramanicin
To investigate whether the endothelial-dependent relaxation following addition of pramanicin is associated with nitric oxide (NO) production, the effect of the NO synthase inhibitor, L-N G -monomethyl-arginine (L-NOARG), on pramanicin-evoked loss of endothelium-dependent relaxation was examined. Figure 4 shows that in endothelium-intact carotid artery rings precontracted with phenylephrine (100 mM), prior treatment with 100 mM L-NOARG, which totally inhibited carbachol (3 mM)-induced relaxation, also inhibited pramanicin (100 mM)-induced slow relaxation without affecting the relaxation evoked by 10 mM SNP. L-NOARG, however, had no effect on the PE plateau responses in the absence of carbachol or pramanicin at either 10 mM or 100 mM PE, suggesting a lack of spontaneous release of NO in dog carotid artery under the in vitro conditions.
DISCUSSION
Pramanicin selectively acts on endothelium-dependent relaxation
We report in this work for the first time the vascular effects of pramanicin, a recently isolated fermentation product with anti-fungal activity. These effects include selective inhibition of endothelium-dependent vascular relaxation induced by carbachol when the vascular preparation was preincubated with pramanicin and a direct relaxant effect when pramanicin was applied at the plateau phase of PE-contrac- Before PMC n 30 min after PMC n 3 mM Carb 80.6 ± 14.5 6 11.6 ± 5.9 6 100 m M ATP 76.9 ± 10.1 6 9.4 ± 7.3 6 3 mM CPA 82.0 ± 17.3 6 13.2 ± 6.7 6 % Relaxation is normalized by the total relaxation of the PE-contraction in response to 10 mM sodium nitroprusside (SNP), which usually inhibited >95% of the PE-contraction. N = number of vascular rings from at least 3 dogs. If the vascular rings were not exposed to PMC between two consecutive applications of the relaxants, similar levels of relaxation (within 10% deviation) were obtained in these two applications of Carb, ATP and CPA under the similar experimental conditions. tion. The former effect was irreversible, suggesting the possible involvement of endothelial cell injury / death, and the latter was inhibited by pretreatment with L-NOARG (also L-N G -monomethyl-arginine (L-NAME), data not shown), suggesting the involvement or occurrence of NO generation from endothelial cells (12) .
The magnitude of maximal contractile responses to KCl and PE, in either endothelium-intact or endothelium-denuded preparations, however, were practically unaffected by pramanicin, applied either prior to or during the plateau phase of the contraction induced by KCl or PE. It was also noted that prolonged exposure of the endothelium-intact vascular preparations to pramanicin, which inhibited the carbacholrelaxation, did not affect the KCl contraction. In fact, the contraction to 100 mM KCl, always carried out at the end of the experiment, in all tissues including those which have been exposed to 100 m M pramanicin, were better than 90% of the same K + -contraction obtained in he beginning of the experiment. These findings together with the ability of the direct smooth muscle relaxant sodium nitroprusside to relax the tissues that were not responsive to either carbachol or pramanicin suggest that the contractile machinery of the smooth muscle cells was not seriously affected by pramanicin compared to the NO-releasing machinery of the endothelial cells within the therapeutic concentration range tested (20 -100 mM).
The apparent lack of sensitivity to pramanicin in vascular smooth muscle contractile function is unlikely to be due to any barrier effect of the endothelium and the advantitia. Despite the general lack of adverse effects of pramanicin on the vascular smooth muscle contractile function, we did observe in about one third of vascular rings (16 out of at least 50 rings) that addition of 100 mM pramanicin caused a small elevation of tone (£10% of the maximal KCl contraction). The nature of this vascular contraction was not further investigated due to its variable occurrence and relatively small size. We conclude that, although pramanicin exerts consistent and selective effects on the endothelial cells, which are in agreement with the observed actions of pramanicin on vascular relaxation, effects on contractions of the vascular smooth muscle cells so far appear to be small and inconsistent.
Pramanicin causes relaxation via endothelium-dependent NO-pathway
The present findings based on contractility studies indicate that prolonged incubation with pramanicin resulted in irreversible functional damage of the endothelial cells, which lose their ability to produce NO upon stimulation by carbachol. On the other hand, the immediate relaxant effect of pramanicin in PE-precontracted vascular rings, which is sensitive to blockade with L-NOARG (L-NAME as well, data not shown) and absent in endothelium-denuded preparations, is apparently due to the stimulation of endothelial NO synthase (eNOS) resulting in NO-mediated vascular relaxation (12, 13) . The time required for the loss of carbachol-induced relaxation of endothelium-intact dog carotid arteries is in reasonable agreement with the time period for dog carotid arteries to reach maximal relaxation from the PE-contraction upon exposure to pramanicin (15 -30 min) . Typically, the irreversible damage of endothelial cell according to the functional test as shown in Table 2 or the trypan blue exclusion test (data not shown) required about 45 min exposure of the vascular tissues to pramanicin, whereas the maximal direct relaxant effect of pramanicin occurred within 15 min after its application to the plateau phase of PE-contraction (Table 1) . Therefore, within the relatively short period (<15 min), the majority of the endothelial cells remained functionally intact and could still produce NO via the NO synthase pathway. The similar IC50 values for pramanicin to relax PE-precontracted rings and to inhibit carbachol-induced relaxation (both being 15 m M, see Fig. 3 ) suggest that these two events are probably mediated via a similar interaction between pramanicin and endothelial cells. It is unlikely that pramanicin acts at the endothelial muscarinic receptor site, because the loss of endothelium-dependent relaxation of dog carotid artery pretreated with pramanicin also occurs when the endothelium-dependent relaxation was induced by ATP (100 mM) or cyclopiazonic acid (3 mM) in PE-precontracted rings as shown by the results in Table 3 .
It is possible that pramanicin-induced NO release and the subsequent cell injury merely represents a progressive increase of membrane permeability resulting from the partition of pramanicin into the lipid bilayers of the cell membrane. The initial increase of membrane permeability to ions, such as Ca
2+
, could account for the generation of NO and associated vascular relaxation (13 -15) . As the membrane permeability continues to increase, the cell membrane may lose its structural integrity, resulting in Ca 2+ overload and the ensuing cell injury and ultimate cell death (16) . It is possible that a specific functional group of the drug may be responsible for its selective action such as NO-mediated relaxation, probably via the elevation of cytosolic Ca 2+ concentration in the endothelial cells. For example, cyclopiazonic acid contains an acyltetramic acid moiety, while pramanicin also contains a modified acyltetramic acid (11) . Both cyclopiazonic acid (14) and pramanicin (this work) cause endothelium-dependent relaxation. Cyclopiazonic acid acts by inhibiting the sarcoplasmic reticulum Ca 2+ -ATPase pump, thus increasing cytosolic Ca 2+ by the capacitative Ca 2+ -entry pathway (7) . It is also possible that the fatty side chain enhances the partition of the drug in the cellular membranes, leading to increased membrane permeability and eventual loss of cell functions. This is exemplified by the finding that lyzophosphatidylcholine, a component of oxidized LDL (17) , elicits a preferential and irreversible effect on vascular endothelial cells (compared to vascular smooth muscle cells) to cause endotheliumdependent relaxation (18) and associated elevation of cell membrane permeability to Ca 2+ (19) . Similarly, the fatty acid side chain of thapsigargin, which is a much more potent specific inhibitor of sarcoplasmic reticulum Ca
-ATPase pump than cyclopiazonic acid, may contribute to the ability of thapsigargin to produce irreversible inhibition (7, 9) . Such a possible mechanism of action of pramanicin on endothelial cell Ca 2+ is currently being investigated using fluorescence ratio microscopy.
Conclusion
We have provided the first functional evidence that in dog carotid arterial rings, pramanicin (30 -100 mM) exerts preferential actions on vascular endothelial cells, causing a slow, irreversible, L-NOARG-sensitive and endotheliumdependent relaxation. The lack of effect of pramanicin on basal tension and KCl contraction, together with the loss of the relaxation response to carbachol following pramanicin treatment, indicated possible selective damage of endothelial cells. Preliminary studies using cultured pulmonary artery endothelial cells indicate that preincubation of these cells with 100 mM pramanicin for 15 -30 min caused substantial cell injury followed by cell death as revealed by the formation of plasma membrane blebs and nuclear staining of trypan blue. This aspect of cell injury is being studied in more detail along with the possibility that pramanicin may cause elevation of cytosolic [Ca 2+ ], which in turn may activate the endothelial nitric oxide synthase and account for the vasorelaxant effect of pramanicin.
